Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

DSpace Repository

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

Author: Kahl, Sabine; Gancheva, Sofiya; Strassburger, Klaus; Herder, Christian; Machann, Juergen; Katsuyama, Hisayuki; Kabisch, Stefan; Henkel, Elena; Kopf, Stefan; Lagerpusch, Merit; Kantartzis, Konstantinos; Kupriyanova, Yuliya; Markgraf, Daniel; van Gemert, Theresa; Knebel, Birgit; Wolkersdorfer, Martin F.; Kuss, Oliver; Hwang, Jong-Hee; Bornstein, Stefan R.; Kasperk, Christian; Stefan, Norbert; Pfeiffer, Andreas; Birkenfeld, Andreas L.; Roden, Michael
Tübinger Autor(en):
Kantartzis, Konstantinos
Stefan, Norbert
Machann, Jürgen
Published in: Diabetes Care (2020), Bd. 43, H. 2, S. 298-305
Verlagsangabe: Amer Diabetes Assoc
Language: English
Full text: http://dx.doi.org/10.2337/dc19-0641
ISSN: 1935-5548
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)